Impedance measurements

Information

  • Patent Grant
  • 8761870
  • Patent Number
    8,761,870
  • Date Filed
    Friday, May 25, 2007
    17 years ago
  • Date Issued
    Tuesday, June 24, 2014
    10 years ago
Abstract
A method of determining frequencies for use in performing impedance measurements. The method includes determining estimates for parameter values representing an impedance response for at least one subject, using the estimated parameter values to determine a design and using the design to determine frequencies for use in impedance measurements.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a §371 national phase of International application PCT/AU2007/000726 filed May 25, 2007, which claims foreign priority to Australian Patent Application no. 2006-902907 filed May 30, 2006.


BACKGROUND OF THE INVENTION

The present invention relates to a method and apparatus for determining frequencies for use in performing impedance measurements on a subject, as well as to a method and apparatus for performing impedance measurements.


DESCRIPTION OF THE PRIOR ART

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.


Bioelectrical Impedance Analysis (BIA) measures the impedance to flow of an alternating electrical current passed through biological tissue. Such impedance measurements are typically performed at a number of different frequencies, allowing a subject's impedance response to be modelled, using a mathematic relationship, such as the Cole model. This in turn enables the estimation of various parameters, which can in turn be used to derive information regarding a subject's health.


However, the frequencies used are typically selected randomly, or based on the ability of the measuring device used to perform the measurements. Consequently the effectiveness and accuracy of the measurements varies greatly.


SUMMARY OF THE PRESENT INVENTION

In a first broad form the present invention provides a method of determining frequencies for use in performing impedance measurements, the method including:

    • a) determining estimates for parameter values representing an impedance response for at least one subject;
    • b) using the estimated parameter values to determine a design; and,
    • c) using the design to determine frequencies for use in impedance measurements.


Typically the method includes, determining the estimates for the parameter values at least in part using a model of the subject's impedance response.


Typically the method includes:

    • a) determining a residual variance model having a predetermined distribution; and,
    • b) determining the estimates for the parameter values at least in part using the selecting variance model.


Typically the method of determining the residual variance model includes using an expectation maximization algorithm.


Typically the method includes determining a range of parameter values representing the impedance response of a number of subjects.


Typically the method includes:

    • a) determining a Fisher information matrix for a model of the impedance response of the at least one subject; and,
    • b) determining a design using the Fisher information matrix.


Typically the model includes at least one of:

    • a) A Cole model; and,
    • b) A residual variance model.


Typically the model includes determining the design by optimising the determinant of the Fisher information matrix.


Typically the design is a D-optimal design.


Typically the method includes determining a design space to take into account practical limitations.


Typically the method includes, modifying the design by at least one of:

    • a) restricting the frequencies; and,
    • b) providing an error structure as a function of frequency.


Typically the method is performed at least in part using a processing system.


Typically the method includes, in the processing system:

    • a) determining impedance data representing the impedance response of the at least one subject; and,
    • b) using the impedance data to determine the estimates for the parameter values.


Typically the method includes, in the processing system:

    • a) determining an impedance model; and,
    • b) using the impedance model and the estimated parameter values to determine the design.


Typically the method includes, in the processing system:

    • a) calculating a Fisher information matrix for the model; and,
    • b) using the Fisher information matrix to determine the design.


Typically the method includes, in the processing system, optimising a determinant of the Fisher information matrix for the model.


Typically the method includes, in the processing system:

    • a) receiving limits on applicable frequencies; and,
    • b) using the limits and the design to determine the frequencies.


Typically the method includes, in the processing system, determining frequencies for use in impedance measurements within the range:

    • a) 0-50 kHz;
    • b) 2-200 kHz;
    • c) 50-500 kHz; and,
    • d) 200-1000 kHz.


Typically the frequencies are within the ranges:

    • a) 0-24 kHz;
    • b) 5-74 kHz;
    • c) 77-200 kHz;
    • d) 530-1000 kHz.


Typically the frequencies are:

    • a) 14 kHz
    • b) 57 kHz
    • c) 188 kHz
    • d) 679 kHz


Typically the frequencies are:

    • a) 14.1844 kHz
    • b) 56.9201 kHz
    • c) 187.5397 kHz
    • d) 679.1141 kHz


In a second broad form the present invention provides apparatus for determining frequencies for use in performing impedance measurements, the apparatus including, a processing system for:

    • a) determining estimates for parameter values representing an impedance response for at least one subject;
    • b) using the estimated parameter values to determine a design; and,
    • c) using the design to determine frequencies for use in impedance measurements.


Typically the apparatus is for performing the first broad form of the invention.


In a third broad form the present invention provides a method of measuring the impedance of a subject the method including, the method including, in a measuring device:

    • a) causing one or more electrical signals to be applied to the subject using a first set of electrodes, the one or more electrical signals having four frequencies;
    • b) measuring electrical signals across a second set of electrodes applied to the subject in response to the applied one or more signals;
    • c) determining from the applied signals and the measured signals at least one measured impedance value at each of the four frequencies, wherein the four frequencies are in the ranges:
      • i) 0-50 kHz;
      • ii) 2-200 kHz;
      • iii) 50-500 kHz; and,
      • iv) 200-1000 kHz.


Typically a restricted range of frequencies can be defined by the ranges:

    • a) 0-24 kHz;
    • b) 5-74 kHz;
    • c) 77-200 kHz;
    • d) 530-1000 kHz.


Typically the frequencies are approximately:

    • a) 14 kHz
    • b) 57 kHz
    • c) 188 kHz
    • d) 679 kHz


Typically the frequencies are:

    • a) 14.1844 kHz
    • b) 56.9201 kHz
    • c) 187.5397 kHz
    • d) 679.1141 kHz


Typically the method includes determining one or more impedance parameter values based on the plurality of measured impedance values.


In a fourth broad form the present invention provides apparatus for measuring the impedance of a subject the apparatus including a measuring device for:

    • a) causing one or more electrical signals to be applied to the subject using a first set of electrodes, the one or more electrical signals having four frequencies;
    • b) measuring electrical signals across a second set of electrodes applied to the subject in response to the applied one or more signals;
    • c) determining from the applied signals and the measured signals at least one measured impedance value at each of the four frequencies, wherein the four frequencies are in the ranges:
      • i) 0-50 kHz;
      • ii) 2-200 kHz;
      • iii) 50-500 kHz; and,
      • iv) 200-1000 kHz.


Typically the measuring device includes:

    • a) a current source for applying current signals to the subject;
    • b) a voltage sensor for measuring voltages signals across the subject; and,
    • c) a processing system could to the current source and the voltage sensor for:
      • i) causing the current signals to be applied to the subject; and,
      • ii) determining the impedance using the applied current signals and measured voltage signals.


Typically the apparatus is for performing the method of the third broad form of the invention.





BRIEF DESCRIPTION OF THE DRAWINGS

Examples of the present invention will now be described with reference to the accompanying drawings, in which:—



FIG. 1 is a flow chart of an example of a process for determining frequencies for use in performing impedance measurements;



FIG. 2 is a schematic diagram of an example of a processing system for use in determining frequencies;



FIG. 3 is a flow chart of a specific example of a process for determining frequencies for use in performing impedance measurements;



FIG. 4 is a schematic diagram of an example of an “idealised” equivalent circuit for the Cole model;



FIG. 5 is a schematic diagram of an example of apparatus for measuring impedance;



FIG. 6 is an example of a residual plot for determining an initial model fit;



FIG. 7 is an example of a resistance versus reactance plot for example impedance measurements;



FIG. 8 is an example of plots of a variance function for various values of σ2; and,



FIG. 9 is an example of a plot of residuals from a model fit using an example extracted data set.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

An example of a process for determining frequencies at which impedance measurements may be made will now be described with reference to FIG. 1.


At step 100 parameter values are determined representing the impedance response of one or more subjects. The parameter values may be determined in any one of a number of manners, such by modelling impedance data collected from a number of subjects from a prior study, as will be described in more detail below.


At step 110 the parameter values are used to determine an optimal design for studying the impedance response of the one or more subjects. This can be achieved, for example, by optimising designs representing frequencies that may be used in performing impedance measurements according to optimality criteria.


At step 120 the optimal designs may optionally be modified to take into account practical effects, such as the variants of subjects within a population to impedance measurement.


At step 130 the optimal designs are used to determine frequencies that may be used for performing impedance measurements.


The process may be performed manually, but typically requires advanced computation and therefore typically requires the use of a processing system.


An example processing system is shown in FIG. 2. In this example, the processing system 200 is formed from a processor 210, a memory 211, an input/output device 212 and an optional external interface 213 interconnected via a bus 214. The external interface 213 may be used to couple the processing system 200 to a database 220.


In use the processing system 200 executes applications software stored in the memory 211, to allow parts of the process to be performed, as will be described in more detail below. It will be appreciated from this that the processing system 200 may be any suitable form of processing system 200, such as a personal computer, desktop, laptop, super computer, Sparc station, or the like.


An example of the process will now be described in more detail with respect to FIG. 3.


In this example, at step 300 impedance data is collected from a sample population of subjects. The data is collected using a suitable measuring device that applies alternating electrical signals to a subject, and measures the electrical response of the subject. This is typically achieved by applying alternating currents to the subject at a number of different frequencies, and then measures voltage signals across the subject, to allow the impedance to be determined at each frequency. An example measuring device will be described in more detail below.


The impedance response of the subject can be modelled using a suitable model, such the Cole model, which is based on an equivalent circuit that effectively models the electrical behaviour of biological tissue, an example of which is shown in FIG. 4.


In this example, the equivalent circuit includes two branches representing current flow through extracellular fluid and intracellular fluid. The extracellular component of biological impedance is represented by a resistance Re, whilst the intracellular component is represented by a resistance Ri and a capacitance C.


Accordingly, the impedance of the equivalent circuit of FIG. 4 at an angular frequency ω, where ω=2π*frequency, is given by:









Z
=


R


+



R
0

-

R




1
+

(

j





ωτ

)








(
A
)









    • where:
      • R=impedance at infinite applied frequency=RiRe/(Ri+Re),
      • R0=impedance at zero applied frequency=Re and,
      • τ is the time constant of the capacitive circuit.





However, as an alternative to the equivalent circuit described above, an alternative equivalent circuit incorporating a Fricke constant phase element (CPE) can be used, as will be understood by persons skilled in the art.


In any event, the equation (A) can be modified to include an exponent α to account for the distribution of time constants observed in biological tissues (or systems), as follows:









Z
=


R


+



R
0

-

R




1
+


(

j





ωτ

)


1
-
α









(
B
)







In this equation, R1, Re, C and α are parameters in the model, Z is the predicted impedance, j=√{square root over (−1)} and f is the frequency of the current passed through the body. R1 and Re are the resistances due to the intracellular and extracellular fluids in the body, respectively.


However, this is a theoretical model and in practice a subject's response will vary. Accordingly, at step 310 a residual variance model is selected to allow variations from the predicted response to be taken into account. The residual variance model may be selected in any one of ways as will be described in more detail below.


At step 320, parameter estimates are determined that represent the measured responses of the subjects. The initial parameters are parameters which when inserted into the models provide an estimate of the response of the sample population.


It will be appreciated that as different subjects within the sample population will have a range of different responses to impedance measurements. Accordingly, it is typical to model the range of responses across the sample population to allow the mean and variability of the parameters between subjects to be determined. This is effectively used to define a range of parameter values representing a parameter space.


At step 330, a number of Cole models are constructed across the parameter space, using the range of parameter values. This effectively models the range of different impedance responses of the subjects within the population.


At step 340 a Fisher information matrix is determined for the residual and Cole models. This can be achieved in any one of a number of ways, but typically involves using suitable applications software, such as the software package POPT by S. B. Duffull, implemented by the processing system 200.


At step 350, the product determinant of the Fisher information matrices is optimised. Again, this may be achieved in any one of a number of manners, such as by using a simulated annealing approach to find maxima for the expression. This provides an optimised design which represents the theoretical preferred frequencies at which impedance measurements may be made.


However, certain frequency measurements may not be practically achievable, or desirable. Thus, for example, theory may predict that the application of an electrical signal 0 kHz frequency will result in an improved subject response and hence improved impedance measurements. However, as the application of such a frequency is not practical, such a frequency is usually excluded. Similarly, high frequency measurements whilst theoretically advantageous, can be difficult to measure from a practical point of view, thereby further limiting the range of available frequencies. Accordingly, at step 360, a design space is selected that can be used to exclude such impractical frequencies.


At step 370 the optimal design can be used to determine preferred practical frequencies at which impedance measurements may be performed, together with an indication of the relative efficiency of the measurement procedure.


Accordingly, the above-described process operates by utilising impedance measurements for a sample population to determine optimal design, which can in turn be used to determine preferred frequencies for performing impedance measurements.


In one example, described in more detail in the specific example below, the process is used to determine that in general at least four frequencies should be used for performing impedance measurements. This can also be used to determine preferred frequency ranges for the four frequencies.


In one example, the preferred frequency ranges are as follows:

    • 0-50 kHz;
    • 2-200 kHz;
    • 50-500 kHz; and,
    • 200-1000 kHz.


Limiting the design space based on practical constraints can lead to more specific frequency ranges as follows:

    • 0-24 kHz;
    • 5-74 kHz;
    • 77-200 kHz;
    • 530-1000 kHz.


Even more preferably, the range of frequencies can be further limited to specific values as follows:

    • 14 kHz
    • 57 kHz
    • 188 kHz
    • 679 kHz


These are based on theoretical preferred frequencies calculated to be as follows:

    • 14.1844 kHz
    • 56.9201 kHz
    • 187.5397 kHz
    • 679.1141 kHz


Determination of the frequencies allows an impedance measuring device to be provided, which is adapted to utilise the preferred frequencies, as shown for example in FIG. 5.


In this example the impedance measuring device typically includes a processing system 1 coupled to a current source 11 and a voltage sensor 12. The current source 11 is coupled via electrodes 13, 14 to a subject S with the voltage sensor being coupled to the subject S via electrodes 15, 16.


In use the processing system 1 causes the current source 11 to apply alternating current signals to the subject S via the electrodes 13, 14, at each of the preferred frequencies determined using the above described process. The response of subject S is then measured via the electrodes 15, 16 using the voltage sensor 12. The processing system 1 can then use details of the applied current and the measured voltage signals to determine an impedance value at each of the preferred frequencies.


By utilising the four measured frequencies, this allows parameters of the Cole model to be determined, such as the subject's impedance at a characteristic frequency Zc, as well as values for the intracellular and extracellular impedance. This in turn allows information such as indicators of the subject's of intracellular or extracellular fluid, or the ratio there between, to be determined.


Specific Example

A specific example of the above process will now be described in more detail.


In this example, the Cole equation described in Cole, K S (1940) Permeability and impermeability of cell membranes for ions Cold Spring Harbor Symposia on Quantitative Biology 8 110-122, is used to model bioimpedance. The model includes nonlinear parameters, which are known to vary between individuals. Accordingly the process uses the theory of experimental design to find the frequencies at which measurements of bioimpedance are optimally made. This can also be used to determine how many frequencies are needed in each patient in order to obtain good estimates of the parameters.


Experimental Design


Much of experimental design focuses on parameter estimation. A design is optimized, that is, the best choice of covariate settings and experimental effort is chosen, through assessment of an optimality criterion. Criteria considered in this paper are D-optimality and product design optimality, which are typically used to gain good parameter estimates for one or more models. Such criteria are based on the expected Fisher information matrix described in more detail below.


A Design ξ is defined by:






ξ
=

{




x
1




w
1






x
2




w
2














x
n




w
n




}







    • where wi is the experimental effort given to the i-th vector of covariates xi.





Use of the experimental effort factor is optional and included in this design for the purpose of example only and the following discussion will focus in examples in which the experimental effort is not taken into account, in which case the preferred Design ξ is defined by:






ξ
=

{




x
1






x
2











x
n




}





If xiεχ, then the design space can be written as






Ξ
=


{


ξ






ɛχ
n

×


[

0
,
1

]

n



:






i
=
1

n



ω
i



=
1

}

.






Fisher Information Matrix


For a model with response vector y=(y1, . . . , yn), dependent upon parameters θ and a design ξ, the expected Fisher information matrix can be defined as:










M


(

θ
,
ξ

)


=

-

E


[




2



l


(

θ
;
y

)






θ





θ





]







(
1
)








where l(θ; y) is the log-likelihood.


The Cramer-Rao lower bound described in H. Cramer “Mathematical methods of statistics.” Princeton, N.J.: Princeton University Press, pages 474-477, 1946, states that the variance-covariance matrix of any unbiased estimator of θ is bounded below by M−1 (θ,ξ). Thus, for given a design ξ, the expected Fisher information indicates how well to estimate the parameters in the model.


D-Optimality


A design ξ is D-optimal if it maximizes the determinant of the expected fisher information matrix. That is, arg maxξ|M(θ,ξ)|. This design will minimize |M−1(θ,ξ) which, minimizes the variance-covariance of {circumflex over (θ)}. Such D-optimal designs, therefore, in general provide good estimates of parameters since they minimise the ellipsoidal confidence regions around an estimate.


When comparing a designs ability to estimate model parameters, its D-efficiency is considered. The D-efficiency of the design ξ compared to the D-optimal design ξ* for a particular model is:









Deff
=

{





M


(

ξ
,
θ

)





1
/

p
1







M


(


ξ
*

,
θ

)





1
/

p
1




}





(
2
)








where pi is the number of parameters in the model.


A D-efficiency of 0.5 for ξ compared with ξ* means that twice as many samples need to be taken using ξ in order to obtain as accurate parameter estimates as given by ξ*.


Product Design Optimality


Product design is found when trying to obtain efficient parameter estimates for more than one model. Here the product of the determinants, scaled by the number of parameters, of each model is maximized giving a design ξ*D1,D2 which should yield good parameter estimates under each model. That is,










ξ


D
1

,

D
2


*

=

arg













max
ξ



{






M
1



(


θ
1

,
ξ

)





1
/

p
1









M
2



(


θ
2

,
ξ

)





1
/

p
2




}







(
3
)








where M11, ξ) is the expected Fisher information matrix for model 1 with parameters θ1 and p1 is the number of model parameters. Similarly for model 2.


Nonlinear Regression


A nonlinear model is specified by two main parts; a function expressing the predicted response and residual response variance structure. This, for the jth observation, can be written as follows:

yj=f(xj,θ)+εj  (4)

where:

    • yj is the jth predicted response,
    • xj are the covariates,
    • θ refers to the model parameters and
    • εj is error or uncertainty in the response for a given individual.


When modelling nonlinear data it is assumed that:

    • (i) E└εj┘=0; for j=1, . . . , m
    • (ii) Cor└εjl=0; for j=1, . . . , m and for l=1, . . . , m
    • (iii) Var[εj]=σ2, and are identically distributed for all xj for j=1, . . . , m;
    • (iv) εj˜N(μ,σ2) for j=1, . . . , m.


Often in practical applications, some of these assumptions do not hold. Accordingly, some generalizations or relaxations of this framework can be used so that the theory of nonlinear regression can be applied in these areas.


One relaxation is a generalization of the assumption of constant variance. Such a relaxation will allow flexibility in specifying intra-individual variance. This involves specifying a variance function h which can depend upon the predicted response E[yj], covariates xj and/or additional parameters δ. The model is then specified by:

E└yj┘=f(xj,θ)
Var[yj]=σ2h2j,xj,δ)
μi=f(xj,θ)


Such a specification generalizes assumption (iii) and allows for heteroscedasticity in the model.


The above defines a fixed effects model. However, to take into account variations between individuals, mixed effects models are typically used.


Fixed Effects Models


For a single individual, a fixed effects model (of the form yi=f(xi,θ)+εi) is considered. The expected fisher information matrix is defined as follows:











-

E


[




2



l


(

θ
;
y

)






θ





θ





]



=

JWJ









where


:








J
=

[







f


(

θ
,
ξ

)






θ
1











f


(

θ
,
ξ

)






θ
2
















f


(

θ
,
ξ

)






θ
n






]






(
5
)








and W is a diagonalized n×1 vector of weights and









f


(

θ
,
ξ

)






θ
i







is a row vector of derivatives of the model with respect to the ith parameter evaluated at the covariates in ξ.


Mixed Effects Models


Mixed effects models allow for the analysis of individual data by incorporating fixed and random effects into a model. This gives two sources of variation; residuals within individuals and variation between individuals. Accordingly, the models have two types of coefficients; population-average and individual specific. One of the main applications of this theory is to repeated measures data.


It is known that where yi is a ni-vector of observations for the i-th individual, where i=1, . . . , N, and let the model be described by F(θii). Then:

yi=fii)+εi(s+tfii))

where ξi=(xi1, . . . , xini)′ is a ni-vector of explanatory variables for the individual i, θi is the p-vector of individual parameters and εi is the ni-vector of random errors.


Here ε is normally distributed with zero mean and a diagonal variance matrix characterized by parameters s and t so that s relates to the additive error component while t relates to the multiplicative error component.


Where θi is defined by β+bi, β is the vector of fixed effects and b is the vector of random effects for individual i. Here bi is normally distributed with mean zero and variance Ω.


The covariates for individual i is denoted by the vector xi, and θi is defined by g(β,bi,xi), where g is a known function. Ψ is an estimate of a vector of all population parameters, let γ be the vector of all variance terms. Then, Ψ′=[β′,γ′]


The Fisher information matrix for a population design








M


(

Ψ
,
Ξ

)


=




i
=
1

N







M


(

Ψ
,

ξ
i


)




,





where Ξ={ξ1, . . . , ξN} and ξi is the ith individual design.


The Fisher information matrix for given values of x is given by:










E

y

x




[

-




2



l


(

θ
;
y

)






θ









θ






]





(
6
)








where l(θ; y) is the log-likelihood of observations y for the population parameters θ. Due to the nonlinearity of f with respect to θ, there is no analytical expression for l(θ; y). That is, in general, for say N individuals where Y is a matrix of responses for the whole population and yi is the vector of responses for the ith individual, the likelihood can be expressed as:











L


(


β
;

Y

x


,
Ω

)


=




i
=
1

N







L
(


β
;


y

i





x
i



,

ω
i


)








where




(
7
)










L


(


β
;


y
i



x
i



,

ω
i


)


=






L
(


β
;

y
i



;





b
i



x
i



,

ω
i


)





b
i










=






L
(


β
;


y
i








b
i



,

x
i


)



L


(


b
i

;

w
i


)






b
i











(
8
)







Given the nonlinearity of bi in f, this integral is generally intractable. One solution for this integral is to approximate the nonlinear function with a first order Taylor expansion around the expected values of the random effects. The model is therefore:









y



f


(


g


(

θ
,

v
_

,
x

)


,
ξ

)


+






f


(

θ
,

v
_

,
x

)



,
ξ




v






(

v
-

v
_


)


+

ɛ


(

s
+

tf


(


g


(

θ
,

v
_

,
x

)


,
ξ

)



)







(
9
)







Then the log-likelihood l is approximated by:











-
2







l


(

θ
;
y

)






n





1





n





2





π

+

1





n



V



+





(



y
i



-

E
i


)






V

-
1


(



y
i



-

E
i


)








(
10
)








where E and V are the marginal expectation and variance of y given by:






E
=


E


(

y

x

)





f


(


g


(

β
,

v
_

,
x

)


,
ξ

)


-





f


(


g


(

β
,

v
_

,
x

)


,
ξ

)






v






v
_













V
=



Var


(

y

x

)








=





[




f


(


g


(

β
,

v
_

,
x

)


,
ξ

)






v




]




Ω


[




f


(


g


(

β
,

v
_

,
x

)


,
ξ

)






v




]





+











diag


(

s
+

tf


(


g


(

β
,

v
_

,
x

)


,
ξ

)



)


2








Then the Fisher information matrix can be expressed as:











M


(

Ψ
,
v
,
x
,
ξ

)


=


1
2



[




A


(

E
,
V

)





C


(

E
,
V

)








C




(

E
,
V

)





B


(

E
,
V

)





]








where









A


(

E
,
V

)


mn

=


2





E






β
m





V

-
1






E




β
n




+

tr


(





E






β
n





V

-
1






E




β
m





V

-
1



)




,






for











m





and





n

=
1

,





,

dim


(
β
)












B


(

E
,
V

)


mn

=

tr


(




V




γ
m





V

-
1






V




γ
n





V

-
1



)



,






for





m





and





n

=
1

,





,

dim


(
γ
)












C


(

E
,
V

)


mn

=

tr


(




V




γ
m





V

-
1






V




β
n




)



,






for





m

=
1

,





,



dim


(
β
)







and





n

=
1

,





,

dim


(
γ
)







(
11
)







Thus, the approximate expected information matrix for a nonlinear mixed effects model is formed. This can now be used in a variety of optimality criteria to form designs with desired properties.


Bioelectrical Impedance Study


The application of these techniques to Bioelectrical impedance analysis (BIA), as modeled using the Cole equation, will now be explained. In particular D-optimal designs are derived based on different assumptions about the interaction between frequency and impedance and also the practical limitations of such a study.


This is achieved by obtaining initial parameter estimates by modeling data on individuals, using these initial estimates to form D-optimal designs and then extending these D-optimal designs so that they perform well in practice.


Optimal Designs for Studying Bioimpedance


In this example the Fisher information matrices are determined using the software package POPT written by S. B. Duffull. The search routine uses an adapted version of a simulated annealing algorithm for continuous variables. Together these techniques provide a means of finding D-optimal designs for nonlinear mixed and fixed effects models across a continuous search space.


Modeling the Data


For the Cole equation, initial parameter estimates were found by modeling paired frequency and bioimpedance data on 61 subjects. Whole-body, wrist to ankle, multifrequency bioimpedance data were recorded over the frequency range 5 to 1024 kHz using an Impedimed-SEAC SFB3 tetra-polar impedance instrument.


Modelling was performed using the software package MONOLIX, which is a MATLAB based package that uses stochastic approximation to the expectation maximization (SAEM) algorithm, in parametric maximum likelihood estimation for nonlinear mixed effects models.


The Expectation-Maximization (EM) algorithm is an iterative procedure used for likelihood function maximization given incomplete data sets formed from observable and non observable data. The E-step in this algorithm cannot be performed in closed formed due to the nonlinearity in f of the random effects, as described above.


The SAEM algorithm replaces this step with a stochastic procedure. Thus, the usual EM algorithm computes, at the kth iteration, the conditional expectation of the log-likelihood giving Qk(Ψ)=E[log p(y,bi;Ψ)|y,Ψk-1)], where p(y,bi;Ψ) is the likelihood of (y,bi).


The SAEM replaces this step by drawing bi(k) from the conditional distribution p(.|y;Ψk) and updates Qk(Ψ) as follows:

Qk(Ψ)=Qk-1(Ψ)+δk(log p(y,bi(k);Ψ)−Qk-1(Ψ))

    • where δk is a decreasing sequence of positive numbers.


To fit a nonlinear model to data, initial parameter estimates are also needed. For this model, initial estimates of fixed effects were taken from previous studies, and estimates of variance were found by what is called a ‘Standard Two Stage Approach’. This involves estimating fixed effects for all data specific to each individual. Then, the variance of these estimates is calculated and used as an estimate for Ω.


The first stage of the modeling process was to find a suitable residual variance model such that the residuals are normally distributed around zero so that tests, such as the likelihood ratio test, are valid. Given the initial estimates, the first run uses a diagonal variance-covariance matrix with all four parameters having a normally distributed random component and the model having additive residuals. The residual plot is shown in FIG. 6.


This shows that the assumption about additive variance holds reasonably well and the residuals are centered around zero. Whilst the plot is not completely random at low frequencies, due for example to technical errors of measurements and inaccuracies associated with using the Cole equation to model bioelectrical impedance, this is considered acceptable.


This additive variance model can then be compared with the multiplicative and additive plus multiplicative error models. The residual plot was best when the additive error model was used.


The initial model can then be compared with different models having various fixed effects parameters. For example, the initial model can be compared with a model setting the parameter c to have no random component to it, that is having a fixed effect only. The likelihood ratio test for nested models can then be used to compare these models with the initial run. In this instance it was found that the initial run significantly increased the log-likelihood to justify having all parameters in the model.


The final step of the modeling process is to allow some or all of the random effects to have a log-normal distribution. This shows that found parameter estimates were not biologically plausible and can therefore be disregarded.


In the end, the initial model chosen to start the modeling process was the one chosen based on the above reasoning. It was also the model that provided the maximum value of the log-likelihood of (y; θ).


Using the model described above, the final estimates can be found in table 1, where the random effects are normally distributed around zero with variance SZ; a diagonal matrix with diagonal elements [ω12, . . . , and ω42] is the residual variance.












TABLE 1







Parameter
Estimate (CV %)




















R0
861.00
(2.04)



Rinf
320
(1.58)



C
2.4e−006
(2.08)



α
0.649
(1.07)



ω12
1.92e+004
(18.39)



ω22
1.66e+003
(19.04)



ω32
1.64e−013
(19.27)



ω42
0.00302
(16.39)



s2
5.46
(0.93)










It will be appreciated that these values are derived from actual physical measurements and will therefore depend on collected data. The above values are therefore for the purpose of illustration only and are not intended to be limiting.


A coefficient of variation (CV %) is calculated by dividing the standard error of an estimate by its estimate and multiplying this by 100 to form a percentage. Typically, acceptable CV %'s for fixed parameters and random parameters are 20% and 50%, respectively. From the table 1, we can see that the CV %'s for our estimates are more than reasonable.


D-Optimal Design for Fixed Effects Model


Examining a design for one individual using the fixed effects model will now be described using the initial estimates found in the previous section, θ=[R0, Rinf, C, α]′=[861, 320, 2.4e−006, 0.649]′. The design which maximises the determinant of the information matrix is:







ξ

D
fixed
*


=

{



0.0001




3.7357




31.8801




1000.0000



}





However, as described above, this is for the values shown in Table 1 and if different values are used, a different matrix will be determined.


D-optimality generally selects extreme values of covariates, but this also occurs to an extent due to the nature of the Cole equation. If ω approaches zero, the Cole equation will approach Z=R0. Alternatively, if ω approaches infinity Z=R. Thus, extreme frequencies provide simpler expressions for R0 and R.


The calculation of the D-efficiency will be described below, providing an indication of the limitation of not accounting for between subject variability seen in the next section.


Mixed Effects


For the Cole equation, parameter estimates are known to vary between subjects, and accordingly a mixed effects model must be used.


For the purpose of this analysis it will be assumed that it is possible to administer electrical currents through the, body at frequencies [0, 1000] kHz, and obtain an accurate reading of bioelectrical impedance Thus, this can assume a model:

yi=f(θ,ξ)+i  (15)


Using the initial estimates from the fixed effects model determined above, and shown in table 1, the following D-optimal design was found by maximizing the determinant of equation 11:







ξ

D
add
*


=

{



0.0001




5.0374




77.4409




1000.0000



}





When forming the expected fisher information matrix for this design, C(E, V) is set to a block matrix of zeros. Then, under this assumption, the fixed and random effects of the model are independent.


The D-efficiency of the fixed effect design under the mixed effects model is 0.9692. Such a high efficiency of the fixed effects D-optimal design suggests that, in this case, accounting for between subject variance only marginally improves the ability to estimate the parameters of the Cole equation.


Dealing with Practical Limitations


With bioelectrical impedance studies, it is known that low and high frequencies produce more highly variable readings of bioimpedance compared with less extreme frequencies.


Two possible approaches to account for this variability will now be described. The first restricts the design space to exclude frequencies where readings of bioimpedance are inaccurate. The second allows the residual variance to depend on the frequency in some manner that mimics real life patterns.


D-optimal Design with Restricted Frequencies


The straight forward approach to dealing with such a variance structure is to avoid frequencies which produce highly variable bioimpedance measures. At present, such bioimpendance studies limit the frequencies to being between a variety of ranges due to this added variability. Examples of such ranges are [4, 200], [4, 500] and [4, 750]. These intervals, therefore are used to define restricted designs.


Allowing parameters to vary between individuals the following D-optimal designs were found for the above example:











TABLE 2







D-eff under Mixed


Range
Frequency
Effects Design

















[4, 200]
4.0000
0.4320



15.1909



60.4311



200.0000


[4, 500]
4.0000
0.5977



18.8903



114.7364



500.0000


[4, 750]
4.0000
0.06752



21.5242



143.0364



750.0000









The D-efficiencies of these restricted designs under the mixed effects models are also shown in table 2. As the range becomes more restricted, the efficiencies decrease. This is highlighted by the D-efficiencies of these designs, which suggest that, under the assumption of constant additive variance, restricting the frequencies to certain intervals creates a significant loss in our ability to estimate parameters precisely. Consequently we will be forced to sample more often in the restricted case to obtain as precise estimates as in the unrestricted case.


D-optimal Design with Variance Function


An assessment of the preferred model can be made by adding a variance function into the model that mimics the variance of bioimpedance in real life studies.


In this case, once the true variance structure has been captured by the function, the D-optimal design will provide the best estimates of the parameters. Inherent in this design will be the ideal range to restrict our frequencies, based on the variance function used.


To achieve this, a model of the following form is used:

yi=fii)+εi(s1+s2h1))  (16)

where h(ξi), a function of frequency, specifies the variance function.


Relaxing the assumption about constant variance of the residuals by forming a variance function described above, allows accurate capture and mimicking of the residual structure, without violating any nonlinear regression assumptions.


Bioimpedance is made up of two parts, resistance and reactance, relating to the real and imaginary parts of the Cole equation, respectively. An example plot of resistance vs reactance is shown in FIG. 7. This plot is of real data and as such shows the real life deviations from the theoretical semi-circle that would be produced from the pure circuit seen in FIG. 4.


The peak of the locus of the semi-circle identifies the characteristic frequency fc. This frequency yields the smallest variance due to the variance function and consequently, it is assumed that at this frequency the constant additive variance dominates. The variance function needs to be such that there is relatively small variance between the chosen interval, for example [4, 750], with rapidly increasing variance for frequencies outside these bounds.


Accordingly, a double exponential model, centred around fc, can be used to adequately model the variance of such a study. Thus, for the range 0 kHz to 1000 kHz, frequencies between fc and 1000 are rescaled to be between 0 and 1. Similarly, frequencies between 0 and fc are rescaled so that they are between 1 and 0. The new vector of rescaled frequencies is then exponentiated twice, and scaled such that the vector has a minimum and a maximum at 0 and 1, respectively. Finally, slightly extra variability is added to frequencies greater than fc by multiplying the resealed numbers which relate to these frequencies by 2. This whole vector is then multiplied by σextra2.


Example residual plots of this variance function h(ξ) for various σextra2 values are shown in FIG. 8. In order to illustrate the variation of impedance at small frequencies, the log of frequency is shown in all four plots.


From this it can be seen that the actual structure of the function does not change, but is merely at a different scale. This also shows how variable readings of bioimpedance can be at low and high frequencies, particularly when σextra2 is large, and how there exists relatively small variance between 4 and 750.


This leads to another consideration for this variance structure, in particular, how much should bioimpedance vary at low and high frequencies, and therefore how large should σextra2 be such that it will capture the real life variance structure of bioimpedance.


Table 3 shows D-optimal designs found for various values of σextra2. The D-efficiencies shown refer to the efficiency of each design compared with the D-optimal design described above. For all designs, the model considered is from equation 16.











TABLE 3





σextra2
ξD*multi
D-eff

















0
0.0001
1.0000



5.0371



77.4409



1000.000


0.1
0.0001
0.6837



15.3454



109.5900



699.9127


0.2
14.6420
0.6383



59.5391



186.4495



680.5794


0.5
20.6291
0.5831



68.7527



183.2815



595.1341


1
25.7367
0.5409



74.3527



175.7765



530.8203









This shows that as the variance increases at the low and high frequencies, the criterion starts to choose frequencies at the less extreme values, thereby avoiding regions which relate to a highly variable reading of bioimpedance. Thus, it is up of the experimenter to decide how variable bioimpedance can be. Once this is decided, the D-optimal design will take this variability into account and find the design which will give the best estimates of parameters.


For example, at a first instance, a broad set of preferred frequency ranges can be defined as follows:

    • 0-50 kHz;
    • 2-200 kHz;
    • 50-500 kHz; and,
    • 200-1000 kHz.


However, using a more limited design space based on the above mentioned practical constraints can lead to more specific frequency ranges as follows:

    • 0-24 kHz;
    • 5-74 kHz;
    • 77-200 kHz;
    • 530-1000 kHz.


In a more extreme limitation, for example, assuming σ2=0.2 is a true representation of the variance, then the optimal design can be seen in the above table, indicating that measurements at frequencies lower than 14.64 kHz and higher than 680.60 kHz are too variable and should be avoided.


Uncertainty in Prior Estimates


Inaccurate prior estimates of parameters for nonlinear models can lead to designs that have a limited ability to estimate parameters that diverse considerably from what was expected. In order to find a design that offers efficient parameter estimates across a wide range of prior estimates, we can look at product design optimality discussed above.


A product design is generally more robust to changes in initial parameter estimates than local D-optimal designs for each parameter set. Thus, a product design is preferred if uncertainty exists in the initial parameter estimates.


Product Design


Given the initial parameters estimates above, 5th and 95th percentiles of the population can be found using the estimates of the between subject variability. For example, given the initial estimate of R0=861 with ω1=138, the 5th and 95th percentiles would be 584 and 1138, respectively.


Such percentiles can be determined for all four model parameters giving a set of eight different initial estimates which would be used as eight different impedance models in the product design. The eight parameter sets considered can be seen in table 4.













TABLE 4





Model
R0
Rinf
C
α



















1
1138
370
2.40e−06
0.6490


2
584
370
2.40e−06
0.6490


3
861
401
2.40e−06
0.6490


4
861
239
2.40e−06
0.6490


5
861
320
3.21e−06

 0.6490 ′



6
861
320
1.59e−06
0.6490


7
861
320
2.40e−06
0.7589


8
861
320
2.40e−06
0.5391









The product design is formed by optimizing over the product of the determinants of the respective variance-covariance matrices of the eight models as a single function. The idea behind forming product designs in this way is that optimizing across all eight models will provide a design which is efficient across a wide range of parameter estimates. The model considered is of the form of equation 16 (σextra2=0.2), the values for which are set out in Table 3 as:







ξ

D
multi
*


=

{



14.6426`




59.5391




186.4495




680.5794



}





The following product design is given by:







ξ


(


D
1

,









,

D
8


)

multi
*


=

{



14.1844




56.9201




187.5397




679.1141



}






Design Evaluation


To analyze how efficient the product design is at estimating parameters across all models, the efficiency of the design under each model is determined, as shown in table 5, in which the efficiency of the product design is compared to each D-optimal design for each parameter set.












TABLE 5







Model
D-eff









1
0.9923



2
0.9932



3
0.9890



4
0.8129



5
0.9573



6
0.7298



7
0.9982



8
0.9997










The efficiency of the product design can be calculated by comparing its D-value under each model compared to the D-optimal value under the respective model. Table 5 shows the efficiency of the product design compared to each D-optimal design for each parameter set. Relatively high efficiencies across all models suggest that the product design is a good means for allowing for uncertainty in initial parameter estimates. Further, given the range of parameter values considered, it is believed that these designs will efficiently estimate model parameters for a variety of individuals. Hence, this approach and the frequencies found should benefit bioimpedance analysis.


A practical approach, applies real data to determine how well model parameters can be estimated. Given the design:







ξ


(


D
1

,









,

D
8


)

multi
*


=

{



14.1844




56.9201




187.5397




679.1141



}






and the data on 61 individuals, impedance at these frequencies were extracted from the data set of all individuals and a nonlinear mixed effects model was fitted to this extracted data set.


Using the same model and initial parameter estimates as discussed in the modelling section above, MONOLIX provides estimates for the parameter values as shown in table 6 and estimates of coefficients of variation found in table 7.













TABLE 6







Parameter
Full Data Set
Extracted Data Set




















R0
861
879



Rinf
320
303



C
2.4e−006
3.25e−006



α
0.649
0.68



ω12
1.92e+004
1.1e+04



ω22
1.66e+003
1.52e+003



ω32
1.64e−013
5.31e−012



ω42
30.2e−003
1.37e−003



s2
5.46
5.24











FIG. 9 shows the residual plot for this fit, indicating that the nonlinear regression assumptions discussed above hold.


The new estimates shown in table 6 are similar to those found using the full data set of observations. Given this and the residual plot, it is concluded that this D-optimal design performs well in practice and as such, with the use of only four frequencies, we have been able to form estimates of parameters of the Cole equation similar to those found by using the full data set.


It is also clear that the product design performs well in practice and requires of only four is frequencies per individual. That is, the optimal choice of these frequencies yields the ability to efficiently estimate model parameters. Further, it highlights the apparent lack of information gained by choosing over 100 unique frequencies per individual to model bioimpedance.


Table 7 shows that the coefficients of variation estimated from the full data set are similar to those estimated from the extracted data set. This suggests that only four measurements of impedance per individual are needed to efficiently estimate the parameters of the Cole equation.













TABLE 7







Full Data Set
Extracted Data Set
Expected





















R0
2.04
1.76
4.15



Rinf
1.58
2.51
6.33



C
2.08
11.11
14.24



α
1.07
1.57
4.74



w12
18.39
20.09
19.14



w22
19.04
22.04
42.18



w32
19.27
24.48
177.34



w42
16.39
28.69
36.82



s2
0.93
12.35
9.80










Table 7 also shows the expected coefficients of variation calculated by using the expected Fisher information matrix to form the expected standard errors of estimates.


Accordingly, this shows that experimental design for nonlinear fixed and mixed effects models can be applied BIA, allowing preferred frequency measuring models to be determined. Numerous four frequency designs were found relating to D-optimal designs based on various assumptions about how frequency relates to bioimpedance and how parameters vary between individuals. Product designs were also found. These designs should be robust to changes in initial estimates.


D-optimal designs can also be applied to real data where it was shown to perform well against the full data set. It is hoped that the D-optimal design approach used here and the designs found will aid BIA researchers in the design of optimised multiple frequency BIA instrumentation. This will mitigate the acknowledged inadequacy of some currently used instrumentation and provide for better clinical utility, for example, the accurate prediction of lean body mass for drug dosing in the obese.


Persons skilled in the art will appreciate that numerous variations and modifications will become apparent. All such variations and modifications which become apparent to persons skilled in the art, should be considered to fall within the spirit and scope that the invention broadly appearing before described.

Claims
  • 1. A method of measuring the impedance of a subject, the method including, in a measuring device including a processing system: a) causing one or more electrical signals to be applied to the subject using a first set of electrodes, the one or more electrical signals having four frequencies;b) measuring electrical signals across a second set of electrodes applied to the subject in response to the applied one or more signals;c) determining from the applied signals and the measured signals at least one measured impedance value at each of the four frequencies, wherein the four frequencies are:i) 14 kHz;ii) 57 kHz;iii) 188 kHz; and,iv) 679 kHz.
  • 2. A method of measuring the impedance of a subject, the method including, in a measuring device including a processing system: a) causing one or more electrical signals to be applied to the subject using a first set of electrodes, the one or more electrical signals having four frequencies;b) measuring electrical signals across a second set of electrodes applied to the subject in response to the applied one or more signals;c) determining from the applied signals and the measured signals at least one measured impedance value at each of the four frequencies, wherein the four frequencies are:i) 14.1844 kHz;ii) 56.9201 kHz;iii) 187.5397 kHz; and,iv) 679.1141 kHz.
  • 3. A method according to claim 1, wherein the method includes determining one or more impedance parameter values based on the plurality of measured impedance values.
  • 4. Apparatus for measuring the impedance of a subject, the apparatus comprising: a first set of electrodes;a second set of electrodes; anda processing unit;wherein the processing unit is configured to:a) cause one or more electrical signals to be applied to the subject using the first set of electrodes, the one or more electrical signals having four frequencies;b) measure electrical signals across the second set of electrodes applied to the subject in response to the applied one or more signals; andc) determine from the applied signals and the measured signals at least one measured impedance value at each of the four frequencies, wherein the four frequencies are:i. 14 kHz;ii. 57 kHz;iii. 188 kHz; andiv. 679 kHz.
  • 5. Apparatus according to claim 4, the measuring device including: a) a current source for applying current signals to the subject;b) a voltage sensor for measuring voltages signals across the subject; and,c) the processing system coupled to the current source and the voltage sensor for: i) causing the current signals to be applied to the subject; and,ii) determining the impedance using the applied current signals and measured voltage signals.
  • 6. Apparatus for measuring the impedance of a subject, the apparatus comprising: a first set of electrodes;a second set of electrodes; anda processing unit;wherein the processing unit is configured to:a) cause one or more electrical signals to be applied to the subject using the first set of electrodes, the one or more electrical signals having four frequencies;b) measure electrical signals across the second set of electrodes applied to the subject in response to the applied one or more signals; andc) determine from the applied signals and the measured signals at least one measured impedance value at each of the four frequencies, wherein the four frequencies are:i. 14.1844 kHz;ii. 56.9201 kHz;iii. 187.5397 kHz; andiv. 679.1141 kHz.
Priority Claims (1)
Number Date Country Kind
2006902907 May 2006 AU national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/AU2007/000726 5/25/2007 WO 00 11/23/2009
Publishing Document Publishing Date Country Kind
WO2007/137333 12/6/2007 WO A
US Referenced Citations (305)
Number Name Date Kind
3316896 Thomasset May 1967 A
3834374 Ensanian et al. Sep 1974 A
3851641 Toole et al. Dec 1974 A
3871359 Pacela Mar 1975 A
4008712 Nyboer Feb 1977 A
4034854 Bevilacqua Jul 1977 A
4144878 Wheeler Mar 1979 A
RE30101 Kubicek et al. Sep 1979 E
4184486 Papa Jan 1980 A
4291708 Frei et al. Sep 1981 A
4314563 Wheeler Feb 1982 A
4353372 Ayer Oct 1982 A
4365634 Bare et al. Dec 1982 A
4401356 Bare Aug 1983 A
4407288 Langer et al. Oct 1983 A
4407300 Davis Oct 1983 A
4450527 Sramek May 1984 A
4458694 Sollish et al. Jul 1984 A
4486835 Bai et al. Dec 1984 A
4537203 Machida Aug 1985 A
4539640 Fry et al. Sep 1985 A
4557271 Stoller et al. Dec 1985 A
4583549 Manoli Apr 1986 A
4602338 Cook Jul 1986 A
4617939 Brown et al. Oct 1986 A
4646754 Seale Mar 1987 A
4686477 Givens et al. Aug 1987 A
4688580 Ko et al. Aug 1987 A
4695955 Faisandier Sep 1987 A
4763660 Kroll et al. Aug 1988 A
4793362 Tedner Dec 1988 A
4832608 Kroll May 1989 A
4890630 Kroll et al. Jan 1990 A
4895163 Libke et al. Jan 1990 A
4905705 Kizakevich et al. Mar 1990 A
4911175 Shizgal Mar 1990 A
4924875 Chamoun May 1990 A
4942880 Slovak Jul 1990 A
4951682 Petre Aug 1990 A
5025784 Shao et al. Jun 1991 A
5063937 Ezenwa et al. Nov 1991 A
5078134 Heilman et al. Jan 1992 A
5086781 Bookspan Feb 1992 A
5101828 Welkowitz et al. Apr 1992 A
5143079 Frei et al. Sep 1992 A
5197479 Hubelbank et al. Mar 1993 A
5199432 Quedens et al. Apr 1993 A
5246008 Mueller Sep 1993 A
5280429 Withers Jan 1994 A
5305192 Bonte et al. Apr 1994 A
5309917 Wang et al. May 1994 A
5311878 Brown et al. May 1994 A
5372141 Gallup et al. Dec 1994 A
5415164 Faupel et al. May 1995 A
5421344 Popp Jun 1995 A
5423326 Wang et al. Jun 1995 A
5449000 Libke et al. Sep 1995 A
5454377 Dzwonczyk et al. Oct 1995 A
5465730 Zadehkoochak et al. Nov 1995 A
5469859 Tsoglin et al. Nov 1995 A
5503157 Sramek Apr 1996 A
5505209 Reining Apr 1996 A
5511553 Segalowitz Apr 1996 A
5526808 Kaminsky Jun 1996 A
5529072 Sramek Jun 1996 A
5544662 Saulnier et al. Aug 1996 A
5557242 Wetherell Sep 1996 A
5562607 Gyory Oct 1996 A
5588429 Isaacson et al. Dec 1996 A
5596283 Mellitz et al. Jan 1997 A
5626146 Barber et al. May 1997 A
5679022 Cappa et al. Oct 1997 A
5704355 Bridges Jan 1998 A
5718231 Dewhurst et al. Feb 1998 A
5732710 Rabinovich et al. Mar 1998 A
5735284 Tsoglin et al. Apr 1998 A
5746214 Brown et al. May 1998 A
5759159 Masreliez Jun 1998 A
5788643 Feldman Aug 1998 A
5800350 Coppleson et al. Sep 1998 A
5807251 Wang et al. Sep 1998 A
5807270 Williams Sep 1998 A
5807272 Kun et al. Sep 1998 A
5810742 Pearlman Sep 1998 A
5876353 Riff Mar 1999 A
5906614 Stern et al. May 1999 A
5919142 Boone et al. Jul 1999 A
5957861 Combs et al. Sep 1999 A
6006125 Kelly et al. Dec 1999 A
6011992 Hubbard et al. Jan 2000 A
6015389 Brown Jan 2000 A
6018677 Vidrine et al. Jan 2000 A
6026323 Skladnev et al. Feb 2000 A
6122544 Organ Sep 2000 A
6125297 Siconolfi Sep 2000 A
6142949 Ubby Nov 2000 A
6151520 Combs Nov 2000 A
6151523 Ferrer et al. Nov 2000 A
6173003 Whikehart et al. Jan 2001 B1
6208890 Sarrazin et al. Mar 2001 B1
6228033 Koobi et al. May 2001 B1
6233473 Shepherd et al. May 2001 B1
6236886 Cherepenin et al. May 2001 B1
6248083 Smith et al. Jun 2001 B1
6256532 Cha Jul 2001 B1
6292690 Petrucelli et al. Sep 2001 B1
6339722 Heethaar et al. Jan 2002 B1
6354996 Drinan et al. Mar 2002 B1
6469732 Chang et al. Oct 2002 B1
6472888 Oguma et al. Oct 2002 B2
6496725 Kamada et al. Dec 2002 B2
6497659 Rafert Dec 2002 B1
6511438 Bernstein et al. Jan 2003 B2
6512949 Combs et al. Jan 2003 B1
6532384 Fukuda Mar 2003 B1
6551252 Sackner et al. Apr 2003 B2
6556001 Wiegand et al. Apr 2003 B1
6560480 Nachaliel et al. May 2003 B1
6561986 Baura et al. May 2003 B2
6569160 Goldin et al. May 2003 B1
6584348 Glukhovsky Jun 2003 B2
6602201 Hepp et al. Aug 2003 B1
6615077 Zhu et al. Sep 2003 B1
6618616 Iijima et al. Sep 2003 B2
6623312 Merry et al. Sep 2003 B2
6625487 Herleikson Sep 2003 B2
6631292 Liedtke Oct 2003 B1
6633777 Szopinski Oct 2003 B2
6636754 Baura et al. Oct 2003 B1
6643543 Takehara et al. Nov 2003 B2
6714813 Ishigooka et al. Mar 2004 B2
6714814 Yamada et al. Mar 2004 B2
6723049 Skladnev et al. Apr 2004 B2
6724200 Fukuda Apr 2004 B2
6725089 Komatsu et al. Apr 2004 B2
6753487 Fujii et al. Jun 2004 B2
6760617 Ward et al. Jul 2004 B2
6768921 Organ et al. Jul 2004 B2
6790178 Mault et al. Sep 2004 B1
6807443 Keren Oct 2004 B2
6829501 Nielsen et al. Dec 2004 B2
6829503 Alt Dec 2004 B2
6845264 Skladnev et al. Jan 2005 B1
6870109 Villarreal Mar 2005 B1
6906533 Yoshida Jun 2005 B1
6922586 Davies Jul 2005 B2
6980852 Jersey-Willuhn et al. Dec 2005 B2
7096061 Arad Aug 2006 B2
7122012 Bouton et al. Oct 2006 B2
7130680 Kodama et al. Oct 2006 B2
7148701 Park et al. Dec 2006 B2
7149573 Wang Dec 2006 B2
7164522 Kimura et al. Jan 2007 B2
7169107 Jersey-Willuhn et al. Jan 2007 B2
7184820 Jersey-Willuhn et al. Feb 2007 B2
7184821 Belalcazar et al. Feb 2007 B2
7186220 Stahmann et al. Mar 2007 B2
7212852 Smith et al. May 2007 B2
7214107 Powell et al. May 2007 B2
7233823 Simond et al. Jun 2007 B2
7251524 Hepp et al. Jul 2007 B1
7270580 Bradley et al. Sep 2007 B2
7353058 Weng et al. Apr 2008 B2
7390303 Dafni Jun 2008 B2
7457660 Smith et al. Nov 2008 B2
7477937 Iijima et al. Jan 2009 B2
7706872 Min et al. Apr 2010 B2
7733224 Tran Jun 2010 B2
7749013 Sato et al. Jul 2010 B2
7907997 Stahmann et al. Mar 2011 B2
20010007056 Linder et al. Jul 2001 A1
20010007924 Kamada et al. Jul 2001 A1
20010020138 Ishigooka et al. Sep 2001 A1
20010025139 Pearlman Sep 2001 A1
20010049479 Szopinski Dec 2001 A1
20010051774 Littrup et al. Dec 2001 A1
20020022787 Takehara et al. Feb 2002 A1
20020072682 Hopman et al. Jun 2002 A1
20020072686 Hoey et al. Jun 2002 A1
20020079910 Fukuda Jun 2002 A1
20020093992 Plangger Jul 2002 A1
20020123694 Organ et al. Sep 2002 A1
20020138019 Wexler et al. Sep 2002 A1
20020161311 Ward et al. Oct 2002 A1
20020163408 Fujii et al. Nov 2002 A1
20020194419 Rajput et al. Dec 2002 A1
20030004403 Drinan et al. Jan 2003 A1
20030004433 Hirschman Jan 2003 A1
20030023184 Pitts-Crick et al. Jan 2003 A1
20030028221 Zhu et al. Feb 2003 A1
20030050570 Kodama Mar 2003 A1
20030068914 Merry et al. Apr 2003 A1
20030073916 Yonce Apr 2003 A1
20030105411 Smallwood Jun 2003 A1
20030120170 Zhu et al. Jun 2003 A1
20030120182 Wilkinson et al. Jun 2003 A1
20030173976 Wiegand et al. Sep 2003 A1
20030216664 Suarez Nov 2003 A1
20040015095 Li Jan 2004 A1
20040019292 Drinan et al. Jan 2004 A1
20040054298 Masuo et al. Mar 2004 A1
20040059242 Masuo et al. Mar 2004 A1
20040073127 Istvan et al. Apr 2004 A1
20040073130 Bohm et al. Apr 2004 A1
20040077944 Steinberg et al. Apr 2004 A1
20040116819 Alt Jun 2004 A1
20040158167 Smith et al. Aug 2004 A1
20040167423 Pillon et al. Aug 2004 A1
20040171963 Takehara Sep 2004 A1
20040181164 Smith et al. Sep 2004 A1
20040186392 Ward et al. Sep 2004 A1
20040204658 Dietz et al. Oct 2004 A1
20040210150 Virtanen Oct 2004 A1
20040210158 Organ et al. Oct 2004 A1
20040234113 Miga Nov 2004 A1
20040236202 Burton Nov 2004 A1
20040242989 Zhu et al. Dec 2004 A1
20040252870 Reeves et al. Dec 2004 A1
20040260167 Leonhardt et al. Dec 2004 A1
20050033281 Bowman et al. Feb 2005 A1
20050039763 Kraemer et al. Feb 2005 A1
20050070778 Lackey et al. Mar 2005 A1
20050080460 Wang et al. Apr 2005 A1
20050098343 Fukuda May 2005 A1
20050101875 Semler et al. May 2005 A1
20050107719 Arad (Abbound) et al. May 2005 A1
20050113704 Lawson et al. May 2005 A1
20050117196 Kimura et al. Jun 2005 A1
20050124908 Belalcazar et al. Jun 2005 A1
20050137480 Alt et al. Jun 2005 A1
20050151545 Park et al. Jul 2005 A1
20050177062 Skrabal et al. Aug 2005 A1
20050192488 Bryenton et al. Sep 2005 A1
20050192511 Shiokawa Sep 2005 A1
20050201598 Harel et al. Sep 2005 A1
20050203435 Nakada Sep 2005 A1
20050215918 Frantz et al. Sep 2005 A1
20050228309 Fisher et al. Oct 2005 A1
20050261743 Kroll Nov 2005 A1
20050283091 Kink et al. Dec 2005 A1
20060004300 Kennedy Jan 2006 A1
20060041280 Stahmann et al. Feb 2006 A1
20060064029 Arad (Abboud) et al. Mar 2006 A1
20060085048 Cory et al. Apr 2006 A1
20060085049 Cory et al. Apr 2006 A1
20060110962 Powell et al. May 2006 A1
20060111652 McLeod May 2006 A1
20060116599 Davis Jun 2006 A1
20060122523 Bonmassar et al. Jun 2006 A1
20060122540 Zhu et al. Jun 2006 A1
20060128193 Bradley et al. Jun 2006 A1
20060135886 Lippert et al. Jun 2006 A1
20060151815 Graovac et al. Jul 2006 A1
20060197509 Kanamori et al. Sep 2006 A1
20060200033 Keren et al. Sep 2006 A1
20060224079 Washchuk Oct 2006 A1
20060224080 Oku et al. Oct 2006 A1
20060241513 Hatlestad et al. Oct 2006 A1
20060241719 Foster et al. Oct 2006 A1
20060247543 Cornish et al. Nov 2006 A1
20060247739 Wahlstrand et al. Nov 2006 A1
20060258952 Stahmann et al. Nov 2006 A1
20060264775 Mills et al. Nov 2006 A1
20060264776 Stahmann et al. Nov 2006 A1
20060270942 McAdams Nov 2006 A1
20060293609 Stahmann et al. Dec 2006 A1
20070007975 Hawkins et al. Jan 2007 A1
20070010758 Matthiessen et al. Jan 2007 A1
20070027402 Levin et al. Feb 2007 A1
20070043303 Osypka et al. Feb 2007 A1
20070049993 Hofmann et al. Mar 2007 A1
20070087703 Li et al. Apr 2007 A1
20070106342 Schumann May 2007 A1
20070156061 Hess Jul 2007 A1
20080001608 Saulnier et al. Jan 2008 A1
20080002873 Reeves et al. Jan 2008 A1
20080004904 Tran Jan 2008 A1
20080009757 Tsoglin et al. Jan 2008 A1
20080009759 Chetham Jan 2008 A1
20080039700 Drinan et al. Feb 2008 A1
20080064981 Gregory Mar 2008 A1
20080205717 Reeves et al. Aug 2008 A1
20080252304 Woo et al. Oct 2008 A1
20080270051 Essex et al. Oct 2008 A1
20080287823 Chetham Nov 2008 A1
20080319336 Ward et al. Dec 2008 A1
20090043222 Chetham Feb 2009 A1
20090054952 Glukhovsky et al. Feb 2009 A1
20090076343 James et al. Mar 2009 A1
20090076345 Manicka et al. Mar 2009 A1
20090076350 Bly et al. Mar 2009 A1
20090082679 Chetham Mar 2009 A1
20090084674 Holzhacker et al. Apr 2009 A1
20090105555 Dacso et al. Apr 2009 A1
20090143663 Chetham Jun 2009 A1
20090177099 Smith et al. Jul 2009 A1
20090264776 Vardy Oct 2009 A1
20090287102 Ward Nov 2009 A1
20090318778 Dacso et al. Dec 2009 A1
20100100003 Chetham et al. Apr 2010 A1
20100109739 Ironstone et al. May 2010 A1
20100145164 Howell Jun 2010 A1
20100168530 Chetham et al. Jul 2010 A1
20100234701 Cho et al. Sep 2010 A1
20110060239 Gaw Mar 2011 A1
Foreign Referenced Citations (133)
Number Date Country
2231038 Nov 1999 CA
2613524 Jan 2007 CA
2615845 Jan 2007 CA
1180513 May 1998 CN
1236597 Dec 1999 CN
1329875 Jan 2002 CN
1366694 Aug 2002 CN
101385203 Mar 2009 CN
2912349 Oct 1980 DE
249823 Dec 1987 EP
339471 Nov 1989 EP
349043 Jan 1990 EP
357309 Mar 1990 EP
377887 Jul 1990 EP
581073 Feb 1994 EP
662311 Jul 1995 EP
865763 Sep 1998 EP
869360 Oct 1998 EP
1078597 Feb 2001 EP
1080686 Mar 2001 EP
1112715 Jul 2001 EP
1114610 Jul 2001 EP
1146344 Oct 2001 EP
1177760 Feb 2002 EP
1219937 Jul 2002 EP
1238630 Sep 2002 EP
1247487 Oct 2002 EP
1283539 Feb 2003 EP
1329190 Jul 2003 EP
1338246 Aug 2003 EP
1452131 Sep 2004 EP
1553871 Jul 2005 EP
1629772 Mar 2006 EP
1903938 Apr 2008 EP
1909642 Apr 2008 EP
1948017 Jul 2008 EP
2486386 Jan 1982 FR
2748928 Nov 1997 FR
2131558 Jun 1984 GB
2260416 Apr 1993 GB
2426824 Dec 2006 GB
04-096733 Mar 1992 JP
06-000168 Jan 1994 JP
8191808 Jul 1996 JP
9051884 Feb 1997 JP
9220209 Aug 1997 JP
10000185 Jan 1998 JP
10014898 Jan 1998 JP
10014899 Jan 1998 JP
10-080406 Mar 1998 JP
10-225521 Aug 1998 JP
11070090 Mar 1999 JP
2000107138 Apr 2000 JP
2000139867 May 2000 JP
2001037735 Feb 2001 JP
2001-070273 Mar 2001 JP
2001061804 Mar 2001 JP
2001-224568 Aug 2001 JP
2001321352 Nov 2001 JP
2002330938 Nov 2002 JP
2003116805 Apr 2003 JP
2005099186 Apr 2005 JP
2005-143786 Jun 2005 JP
2008022995 Feb 2008 JP
001019789 Jul 2003 NL
2112416 Jun 1998 RU
2138193 Sep 1999 RU
1132911 Jan 1985 SU
8807392 Oct 1988 WO
9318821 Sep 1993 WO
9410922 May 1994 WO
9601586 Jan 1996 WO
9612439 May 1996 WO
9632652 Oct 1996 WO
9711638 Apr 1997 WO
9714358 Apr 1997 WO
9743000 Nov 1997 WO
9806328 Feb 1998 WO
9823204 Jun 1998 WO
9833553 Aug 1998 WO
9851211 Nov 1998 WO
9854792 Dec 1998 WO
0019886 Apr 2000 WO
0040955 Jul 2000 WO
0079255 Dec 2000 WO
0127605 Apr 2001 WO
0150954 Jul 2001 WO
0167098 Sep 2001 WO
0178831 Oct 2001 WO
0182323 Nov 2001 WO
0247548 Jun 2002 WO
02062214 Aug 2002 WO
02094096 Nov 2002 WO
02100267 Dec 2002 WO
2004000115 Dec 2003 WO
2004026136 Apr 2004 WO
2004030535 Apr 2004 WO
2004032738 Apr 2004 WO
2004047636 Jun 2004 WO
2004048983 Jun 2004 WO
2004047635 Jun 2004 WO
2004047638 Jun 2004 WO
2004049936 Jun 2004 WO
2004083804 Sep 2004 WO
2004084723 Oct 2004 WO
2004084724 Oct 2004 WO
2005010640 Feb 2005 WO
2005018432 Mar 2005 WO
2005027717 Mar 2005 WO
2005051194 Jun 2005 WO
2005084539 Sep 2005 WO
2005122888 Dec 2005 WO
2005122881 Dec 2005 WO
2006129108 Dec 2006 WO
2006129116 Dec 2006 WO
2007002993 Jan 2007 WO
2007002991 Jan 2007 WO
2007002992 Jan 2007 WO
2007009183 Jan 2007 WO
2007014417 Feb 2007 WO
2007041783 Apr 2007 WO
2007089278 Aug 2007 WO
2008064426 Jun 2008 WO
2008119166 Oct 2008 WO
2008138062 Nov 2008 WO
2009036369 Mar 2009 WO
2009059351 May 2009 WO
2009100491 Aug 2009 WO
2010051600 May 2010 WO
2010060152 Jun 2010 WO
2011022068 Feb 2011 WO
2011050393 May 2011 WO
2011075769 Jun 2011 WO
Non-Patent Literature Citations (78)
Entry
Liu et al., Primary Multi-frequency Data Analyze in Electrical Impedance Scanning, Proceedings of the IEEE-EMBS 2005, 27th Annual Int'l Conference of the Engineering in Med. and Biology Soc., Shanghai, China, Sep. 4, 2005; 1504-1507.
Gudivaka et al., Single- and multifrequency models for bioelectrical impedance analysis of body water compartments, Appl. Physiol., 1999; 87(3), 1087-96.
U.S. Appl. No. 13/128,631, Essex et al.
U.S. Appl. No. 13/131,859, Gaw.
U.S. Appl. No. 12/090,078, filed Feb. 12, 2009, Chetham.
U.S. Appl. No. 12/516,876, filed Jul. 1, 2010, Chetham.
U.S. Appl. No. 12/596,833, filed Jun. 17, 2010, Ward.
U.S. Appl. No. 12/600,224, Chetham.
U.S. Appl. No. 12/672,893, filed Feb. 24, 2011, Cornish.
U.S. Appl. No. 10/767,825, filed Sep. 23, 2004, Ward.
d'Entremont et al. “Impedance spectroscopy: an accurate method of differentiating between viable and ischaemic or infarcted muscle tissue” Med. Biol. Eng. Comput., 2002, 40: 380-87.
Zhu et al., “Dynamics of segmental extracellular volumes during changes in body position by bioimpedance analysis”; J. App. Physiol.; 1998, vol. 85, pp. 497-504.
McCullagh, W. A., et al., Bioelectrical impedance analysis measures the ejection fraction of the calf muscle pump, IFMBE Proceedings, 2007; vol. 17, p. 619.
European Search Report for EP 07718972.8-1265 / 2020918 (Impedimed, Ltd.), mailed on Mar. 2, 2010, 4 pages.
Brown et al.; Relation between tissue structure and imposed electrical current flow in cervical neoplasis; The Lancet; Mar. 11, 2000; vol. 355, Issue 9207: pp. 892-895.
Ellis et al.; Human hydrometry: comparison of multifrequency biolectrical impedance with 2H2O and bromine dilution; Journal of Applied Physiology; 1998; 85(3): 1056-1062.
Jones et al.; Extracellular fluid volume determined by bioelectric impedance and serum albumin in CAPD patients; Nephrology Dialysis Transplantation; 1998; 13: 393-397.
Thomas B.J.; Future technologies; Asia Pacific Journal Clinical Nutrition; 1995; 4: 157-159.
Schneider, I.; Broadband signals for electrical impedance measurements for long bone fractures; Engineering in Medicine and Biology Society, 1996. Bridging Disciplines for Biomedicine. Proceedings of the 18th Annual International Conference of the IEEE; Oct. 31, 1996; 5: 1934-1935.
Woodrow et al.; Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis; Nephrology Dialysis Transplantation; 2000; 15: 862-866.
Boulier et al.; Fat-Free Mass Estimation by Two Electrode Impedance Method; American Journal of Clinical Nutrition; 1990; 52: 581-585.
McDougal et al.; Body Composition Measurements from Whole Body Resistance and Reactance; Surgical Forum; 1986; 36: 43-44.
Tedner, B.; Equipment using Impedance Technique for Automatic Recording of Fluid-Volume Changes during Hemodialysis; Medical & Biological Engineering & Computing; 1983; 285-290.
Lukaski et al.; Estimation of Body Fluid Volumes using Tetrapolar Bioelectrical Impedance Measurements; Aviation, Space, and Environmental Medicine; Dec. 1988; 1163-1169.
Lozano et al.; Two-frequency impedance plethysmograph: real and imaginary parts; Medical & Biological Engineering & Computing; Jan. 1990; 28(1): 38-42.
Chaudary et al.; Dielectric Properties of Normal & Malignant Human Breast Tissues at Radiowave and Microwave Frequencies; Indian Journal of Biochemistry & Biophysics; 1984; 21(1): 76-79.
Jossinet et al.; A study for breast imaging with a circular array of impedance electrodes; Proc. Vth Int. Conf. Bioelectrical Impedance, 1981, Tokyo, Japan; 1981; 83-86.
Jossinet et al.; Technical Implementation and Evaluation of a Bioelectrical Breast Scanner; Proc. 10.supth Int. Conf. IEEE Engng. Med. Biol., 1988, New Orleans, USA (Imped. Imaging II); 1988; 1: 289.
Man et al.; Results of Preclinical Tests for Breast Cancer Detection by Dielectric Measurements; XII Int. Conf. Med. Biol. Engng. 1979, Jerusalem, Israel. Springer Int., Berlin; 1980; Section 30.4.
Pethig et al.; The Passive Electrical Properties of Biological Systems: Their Significance in Physiology, Biophysics and Biotechnology; Physics in Medicine and Biology; 1987; 32: 933-970.
Piperno et al.; Breast Cancer Screening by Impedance Measurements; Frontiers of Medical & Biological Engineering; 1990; 2: 111-117.
Skidmore et al.; A Data Collection System for Gathering Electrical Impedance Measurements from the Human Breast; Clinical Physics Physiological Measurement; 1987; 8: 99-102.
Sollish et al.; Microprocessor-assisted Screening Techniques; Israel Journal of Medical Sciences; 1981; 17: 859-864.
Surowiec et al.; Dielectric Properties of Breast Carcinima and the Surrounding Tissues; IEEE Transactions on Biomedical Engineering; 1988; 35: 257-263.
Al-Hatib, F.; Patient Instrument Connection Errors in Bioelectrical Impedance Measurement; Physiological Measurement; May 2, 1998; 19(2): 285-296.
Gersing, E.; Impedance Spectroscopy on Living Tissue for Determination of the State of Organs; Bioelectrochemistry and Bioenergetics; 1998; 45: 145-149.
Mattar, J.A.; Application of Total Body Impedance to the Critically Ill Patient; New Horizons; 1996; 4(4): 493-503.
Ott et al.; Bioelectrical Impedance Analysis as a Predictor of Survival in Patients with Human Immunodeficiency Virus Infection; Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology; 1995; 9: 20-25.
Thomas et al.; Bioelectrical impedance analysis for measurement of body fluid volumes—a review; Journal of Clinical Engineering; 1992; 17(16): 505-510.
Ward et al.; There is a better way to measure Lymphedema; National Lymphedema Network Newsletter; Oct. 1995; 7(4): 89-92.
Cornish et al.; Alteration of the extracellular and total body water volumes measured by multiple frequency bioelectrical impedance analysis; Nutrition Research; 1994; 14(5): 717-727.
Cornish et al.; Early diagnosis of lymphedema using multiple frequency bioimpedance; Lymphology; Mar. 2001; 34: 2-11.
Cornish et al.; Early diagnosis of lymphoedema in postsurgery breast cancer patients; Annals New York Academy of Sciences; May 2000; 571-575.
Brown et al.; Relation between tissue structure and imposed electrical current flow in cervical neoplasia; The Lancet; Mar. 11, 2000; 355 (9207): 892-895.
Iacobellis, G. et al.; Influence of excess fat on cardiac morphology and function: Study in Uncomplicated obesity; Obesity Research; Aug. 8, 2002; 10 (8): 767-773.
Bella, J. N. et al.; Relations of left ventricular mass to fat-free and adipose body mass: The Strong Heart Study; Circulation; Dec. 12, 1998; 98: 2538-2544.
Yoshinaga, M. et al.; Effect of total adipose weight and systemic hypertension on left ventricular mass in children; American Journal of Cardiology; Oct. 15, 1995; 76: 785-787.
Karason, K. et al.; Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure; European Heart Journal; Jan. 1, 2003; 24: 1500-1505.
Abdullah M. Z.; Simulation of an inverse problem in electrical impedance tomography using resistance electrical network analogues; International Journal of Electrical Engineering Education; Oct. 1999; 36 (4): 311-324.
Dines et al.; Analysis of electrical conductivity imaging; Geophysics; Jul. 1981; 46 (7): 1025-1036.
Osterman et al.; Multifrequency electrical impedance imaging: preliminary in vivo experience in breast; Physiological Measurement; Feb. 2000; 21 (1): 99-109.
Ward et al.; Determination of Cole parameters in multiple frequency bioelectrical impedance analysis using only the measurement of impedances; Four-frequency fitting; Physiological Measurement; Sep. 2006; 27 (9): 839-850.
Bernstein; A new stroke volume equation for thoracic electrical bio impedance; Critical Care Medicine; 1986; vol. 14; pp. 904-909.
McAdams et al.; Tissue Impedance: a historical overview; Physiological Measurement, Institute of Physics Publishing, Bristol, GB; 16 (3A); pp. A1-A13; Aug. 1, 1995.
Forslund et al., Evaluation of modified multicompartment models to calculate body composition in healthy males, Am. J. of Clin. Nutrition, 1996; 63:856-62.
Van Loan et al., Use of bioelectrical impedance spectroscopy (BIS) to measure fluid changes during pregnancy, J. Appl. Physiol., 1995; 78:1037-42.
De Lorenzo et al., Predicting body cell mass with bioimpedance by using theoretical methods: a technological review, J. Appl. Physiol., 1997; 82(5):1542-58.
Zhu et al., Segment-specific resistivity improves body fluid volume estimates from bioimpedance spectroscopy in hemodialysis patients, J. Appl. Physiol., Oct. 27, 2005; 100:717-24.
Thomas et al., Bioimpedance Spectrometry in the Determination of Body Water Compartments: Accuracy and Clinical Significance, Applied Radiation and Isotopes, 1998; 49(5/6):447-455, Elsevier Science Ltd., Oxford, GB.
Cornish et al., Data analysis in multiple-frequency bioelectrical impedance analysis, Physiological Measurement, 1998; 19(2):275-283, Institute of Physics Publishing, Bristol, GB.
Ulgen et al., Electrical Parameters of Human Blood, Proc. of the 20th Annual Int'l Conference of the IEEE Engineering in Medicine and Biology Soc., 1998; 20(6):2983-2986, IEEE Piscataway, NJ.
Bracco et al., Bedside determination of fluid accumulation after cardiac surgery usign segmental bioelectrical impedance, 1998, Critical Care Medicine, vol. 26 No. 6, pp. 1065-1070.
Chiolero et al., Assessmetn of changes in body water by bioimpedance in acutely ill surgical patients, 1992, Intensive Care Medicine, vol. 18, pp. 322-326.
Chumlea et al., Bioelectrical impedance and body composition: present status and future directions, 1994 Nutrition Reviews, vol. 52, No. 4, pp. 123-131.
Cornish et al., Bioelectrical impedance for monitoring the efficacy of lymphoedema treatment programmes, 1996, Breast Cancer Research and Treatment, vol. 38, pp. 169-176.
Cornish et al., Quantification of lymphoedema using multi-frequency bioimpedance, 1998, Applied Radiation and Isotopes, vol. 49 No. 5/6, pp. 651-652.
De Luca et al., Use of low-frequency electrical impedance mesurements to determine phospholipid content in amniotic fluid, 1996, Physics in Medicine and Biology, vol. 41, pp. 1863-1869.
Derwent Abstract No. 97-474414, JP 09 220209 A (Sekisui Chem Ind Co Ltd) Aug. 26, 1997, see abstract.
Derwent Abstract No. 99-138541, JP 10 014898 A (Sekisui Chem Ind Co Ltd) Jan. 20, 1998, see abstract.
Derwent Abstract No. 99-138542, JP 10 014899 A (Sekisui Chem Ind Co Ltd) Feb. 20, 1998, see abstract.
Derwent Abstract No. 99-247542, JP 11 070090 A (Sekisui Chem Ind Co Ltd) Mar. 16, 1999, see abstract.
Duerenberg et al., Multi-frequency bioelectrical impedance: a comparison between the Cole-Cole modelling and Hanai equations with the classical impedance index approach, 1996, Annals of Human Biology, vol. 23, No. 1, pp. 31-40.
Kim et al., Bioelectrical impedance changes in regional extracellular fluid alterations, 1997, Electromyography and Clinical Neurophysiology, vol. 37, pp. 297-304.
Rigaud et al., Biolectrical impedance techniques in medicine, 1996, Critical Reviews in Biomedical Engineering, vol. 24 (4-6), pp. 257-351.
Steijaert et al., The use of multi-frequency impedance to determine total body water and extracellular water in obese and lean female individuals, 1997, International Journal of Obesity, vol. 21, pp. 930-934.
Ward et al., Multi-frequency bioelectrical impedance augments the diagnosis and management of lymphoedema in post-mastectomy, 1992, European Journal of Clinical Investigation, vol. 22, pp. 751-754.
Gerth et al., A Computer-based Bioelectrical Impedance Spectroscopic System for Noninvasive Assessment of Compartmental Fluid Redistribution, Third Annual IEEE Symposium on Computer-Based Medical Systems Track 6: Clinical Assessment and Risk Evaluation/Session 13, 1990; 446-453.
Kanai et al., Electrical measurement of fluid distribution in legs and arms, Dept. of Electrical Engineering, Sophia University, 1987; Medical Progress through Technology 12: 159-170, Copyright Martinus Nijhoff Publishers, Boston, MA USA.
Related Publications (1)
Number Date Country
20100087750 A1 Apr 2010 US